Patents Assigned to Kitasato Institute
-
Patent number: 10285618Abstract: An electrical impedance tomography (EIT) measurement device (1) includes a measurement belt (10) to which a plurality of electrode pads arranged in a row and a plurality of strain gauges arranged in parallel to the plurality of electrode pads are integrally adhered and configured to be used after being wrapped around a portion (X) serving as a measurement target of a living body, an EIT measurement control unit configured to acquire a tomographic image of the portion (X) serving as the measurement target while applying a current to the plurality of electrode pads and acquiring a voltage signal generated between the electrode pads, and a contour estimation unit configured to estimate a contour shape of the portion serving as the measurement target and a size of the contour shape on the basis of curvature data acquired via the strain gauge.Type: GrantFiled: July 1, 2014Date of Patent: May 14, 2019Assignee: SCHOOL JURIDICAL PERSON KITASATO INSTITUTEInventors: Satoru Nebuya, So Hifumi
-
Patent number: 10213488Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. Methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. In addition, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.Type: GrantFiled: December 21, 2016Date of Patent: February 26, 2019Assignees: The Board of Trustees of the University of Arkansas, The Kitasato Institute, Montefiore Medical CenterInventors: Tulasi Ponnapakkam, Sagaya Theresa Leena Philominathan, Joshua Sakon, Ranjitha Katikaneni, Takaki Koide, Osamu Matsushita, Robert C. Gensure
-
Patent number: 10202627Abstract: An object of the present invention is to provide enzymes and a DNA encoding the enzymes that are involved in biosynthesis of trehangelin which has the potential to be a therapeutic agent for photosensitivity disorder and cosmetics, and to provide a method for producing trehangelin by utilizing the enzymes and a recombinant microorganism. The present invention is directed to a protein having an amino acid sequence of SEQ ID NO: 3, 5, 7 or 9, or a protein having an amino acid sequence of SEQ ID NO: 3, 5, 7 or 9 in which one to several amino acids are deleted, substituted, added and/or inserted or an amino acid sequence having 60% or more homology with the amino acid sequence of SEQ ID NO: 3, 5, 7 or 9 and having an enzyme activity involved in biosynthesis of trehangelin; and a DNA encoding said protein.Type: GrantFiled: February 28, 2017Date of Patent: February 12, 2019Assignees: The Kitasato Institute, Nagase & Co., Ltd.Inventors: Satoshi Omura, Yoko Takahashi, Takuji Nakashima, Yuki Inahashi
-
Publication number: 20180057493Abstract: A morphinan derivative represented by the following general formula (I): (wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc., R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group, Y binds to a carbon atom as a ring-constituting atom of R2, R3, R4, and R5 represent hydrogen; hydroxy, etc., R6a and R6b represent hydrogen, etc., R7 and R8 represent hydrogen, etc., R9 and R10, which are the same or different, represent hydrogen, etc., X represents O or CH2, and Y represents C(?O)), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.Type: ApplicationFiled: March 17, 2016Publication date: March 1, 2018Applicants: UNIVERSITY OF TSUKUBA, SCHOOL JURIDICAL PERSON KITASATO INSTITUTE, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, NIPPON CHEMIPHAR CO., LTD.Inventors: Hiroshi NAGASE, Hideaki FUJII, Akiyoshi SAITOH, Eriko NAKATA, Masaaki HIROSE, Isao OOI, Kohei HAYASHIDA
-
Patent number: 9896456Abstract: This invention provides a novel non-natural pharmaceutical compound having a different mechanism than statin drugs and having a selective inhibitory activity against ACAT2.Type: GrantFiled: June 18, 2015Date of Patent: February 20, 2018Assignee: School Juridical Person Kitasato InstituteInventors: Hiroshi Tomoda, Masaki Ohtawa, Satoshi Omura, Tohru Nagamitsu
-
Patent number: 9737558Abstract: The present invention provides a Peyer's patch activator containing a polysaccharide obtained from sugar cane as an active ingredient, wherein the polysaccharide contains ?-glucan as a main component and has a peak molecular weight within a range of 720,000 to 1,080,000, with a proportion of glucose in all component sugars being 80% or more, and proportions of nonreducing terminal glucose and ?-1,6-linked glucose being 20 to 30% and 15 to 25%, respectively.Type: GrantFiled: September 18, 2013Date of Patent: August 22, 2017Assignees: Mitsui Sugar Co., Ltd., The Kitasato InstituteInventors: Haruki Yamada, Hiroaki Kiyohara, Kazuhiko Otoguro, Aki Ishiyama, Masato Iwatsuki, Satoshi Omura, Masami Mizu, Toshikazu Kawai, Jun Kashimura, Kenji Koge
-
Publication number: 20170202762Abstract: Provided are: a method for producing a mycrosporine-like amino acid (MAA) that includes a step in which microbes are cultivated that produce MAA on the outside of bacterial cells, a step in which the bacterial cells and extracellular culture fluid are separated, and a step in which the MAA is recovered from the extracellular culture fluid; an MAA indicated by formula (1), an MAA produced using this method, or an ultraviolet-absorbing composition including the MAA indicated by formula (1); and a composition including the MAA produced using this method or the MAA indicated by formula (1), for preventing at least one symptom or disease selected from a group comprising acute skin reactions, aging of the skin, and skin cancer.Type: ApplicationFiled: May 12, 2015Publication date: July 20, 2017Applicants: THE KITASATO INSTITUTE, NAGASE & CO., LTD.Inventors: Haruo IKEDA, Shogo YAMAMOTO, Jun MATSUMOTO, Masahiro SOTA
-
Publication number: 20170204390Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.Type: ApplicationFiled: January 17, 2017Publication date: July 20, 2017Applicants: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS, The Kitasato Institute, MONTEFIORE MEDICAL CENTER, NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERISTYInventors: Tulasi Ponnapakkam, Sagaya Theresa Leena Philominathan, Joshua Sakon, Ranjitha Katikaneni, Takaki Koide, Osamu Matsushita, Robert C. Gensure, Nozomu Nishi
-
Publication number: 20170204114Abstract: This invention provides a novel non-natural pharmaceutical compound having a different mechanism than statin drugs and having a selective inhibitory activity against ACAT2.Type: ApplicationFiled: June 18, 2015Publication date: July 20, 2017Applicant: School Juridical Person Kitasato InstituteInventors: Hiroshi Tomoda, Masaki Ohtawa, Satoshi Omura, Tohru Nagamitsu
-
Publication number: 20170199143Abstract: A detection device includes: a frequency property acquisition unit that acquires a frequency property when an alternating-current signal is input to at least two conductive bodies provided on a fiber sheet; and a detection signal output unit that outputs a detection signal when the frequency property acquisition unit acquires a predetermined frequency property.Type: ApplicationFiled: April 7, 2015Publication date: July 13, 2017Applicant: School Juridical Person Kitasato InstituteInventor: Satoru NEBUYA
-
Publication number: 20170157569Abstract: A blood purifier comprises hollow fiber membranes allowing a dialysing fluid or a filtrated fluid to flow outside. The membrane has an effective length of 10 mm or more and 150 mm or less. A maximum value of a permeation flux Jv obtained by dividing a volume of a permeate fluid permeating through the membranes by a membrane area of the hollow fiber membranes and time, is represented as Jvmax. A linear velocity of blood flowing in the membrane is represented as uB. A pressure difference between blood flowing inside the membranes and a fluid flowing outside the membranes is represented as TMP. When a filling blood volume into the membranes per unit membrane area is 20 mL/m2 or more and 35 mL/m2 or less and Jvmax/uB has a value of 0.00015 or more and 0.0006 or less, a TMP change rate is 0.95 or more and 1.05 or less.Type: ApplicationFiled: July 8, 2014Publication date: June 8, 2017Applicants: UNIVERSITY OF YAMANASHI, SCHOOL JURIDICAL PERSON KITASATO INSTITUTE, NIPRO CORPORATIONInventors: Kenichi MATSUDA, Kenichi KOKUBO, Hirosuke KOBAYASHI, Takashi SUNOHARA, Syunsuke NOTAZAWA, Hiroshi FUKUSHIMA
-
Publication number: 20170106093Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. Methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. In addition, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.Type: ApplicationFiled: December 21, 2016Publication date: April 20, 2017Applicants: The Board of Trustees of the University of Arkansas, The Kitasato Institute, Montefiore Medical CenterInventors: Tulasi Ponnapakkam, Sagaya Theresa Leena Philominathan, Joshua Sakon, Ranjitha Katikaneni, Takaki Koide, Osamu Matsushita, Robert C. Gensure
-
Patent number: 9624223Abstract: The present invention relates to a morphinan derivative represented by the following general formula (I), wherein R1 represents hydrogen, C1-6 alkyl, C6-10 aryl, etc., R2 and R3, which are the same or different, represent hydrogen, hydroxy, etc., R4 and R5 represent hydrogen, C1-6 alkyl, etc., R6 represents hydrogen, hydroxy, C1-6 alkyl, etc., X represents O or CH2, Y represents C?O, C(?O)O, etc., and m and n, which are the same or different, represent an integer of 0 to 2 (m and n are not 0 at the same time), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as an analgesic, antianxiety drug, etc. containing the same as an active ingredient.Type: GrantFiled: October 15, 2013Date of Patent: April 18, 2017Assignees: THE KITASATO INSTITUTE, NIPPON CHEMIPHAR CO., LTD.Inventors: Hiroshi Nagase, Hideaki Fujii, Eriko Nakata, Yoshikazu Watanabe, Daisuke Saito, Toshihiro Takahashi
-
Patent number: 9579273Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.Type: GrantFiled: December 14, 2012Date of Patent: February 28, 2017Assignees: The Kitasato Institute, National University Corporation Kagawa UniversityInventors: Tulasi Ponnapakkam, Sagaya Theresa Leena Philominathan, Joshua Sakon, Ranjitha Katikaneni, Takaki Koide, Osamu Matsushita, Robert C. Gensure, Nozomu Nishi
-
Patent number: 9526765Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. Methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. In addition, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.Type: GrantFiled: February 11, 2013Date of Patent: December 27, 2016Assignees: The Kitasato InstituteInventors: Tulasi Ponnapakkam, Sagaya Theresa Leena Philominathan, Joshua Sakon, Ranjitha Katikaneni, Takaki Koide, Osamu Matsushita, Robert C. Gensure
-
Patent number: 9380933Abstract: The present invention accurately predicts postoperative intraocular lens position on the basis of a shape image of the crystalline lens obtained by an optical interference tomographic imaging device. This makes it possible to reduce the postoperative refractive error and determine the power of the intraocular lens. The present invention comprises: a step for finding by computer the equatorial position, which is the site of maximum diameter in the crystalline lens, from the morphology of the crystalline lens obtained from a tomographic image of the patients eye generated by the optical interference tomographic imaging device; and a step for estimating the position of the intraocular lens from the equatorial position thus found.Type: GrantFiled: December 9, 2014Date of Patent: July 5, 2016Assignee: SCHOOL JURIDICAL PERSON KITASATO INSTITUTEInventor: Shuntaro Tsunehiro
-
Publication number: 20160122349Abstract: The present invention relates to a morphinan derivative represented by the following general formula (I), wherein R1 represents hydrogen, C1-6 alkyl, C6-10 aryl, etc., R2 and R3, which are the same or different, represent hydrogen, hydroxy, etc., R4 and R5 represent hydrogen, C1-6 alkyl, etc., R6 represents hydrogen, hydroxy, C1-6 alkyl, etc., X represents O or CH2, Y represents C?O, C(?O)O, etc., and m and n, which are the same or different, represent an integer of 0 to 2 (m and n are not 0 at the same time), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as an analgesic, antianxiety drug, etc. containing the same as an active ingredient.Type: ApplicationFiled: October 15, 2013Publication date: May 5, 2016Applicants: THE KITASATO INSTITUTE, NIPPON CHEMIPHAR CO., LTD.Inventors: Hiroshi NAGASE, Hideaki FUJII, Eriko NAKATA, Yoshikazu WATANABE, Daisuke SAITO, Toshihiro TAKAHASHI
-
Patent number: 9248164Abstract: Provided is a growth factor anchoring type bone graft material, wherein a bone graft substrate exposing at least a collagen fiber is bound to a collagen-binding-site-containing growth factor which contains a growth factor receptor agonist peptide and a collagen-binding peptide. The same can be produced by mixing a bone graft substrate and a collagen-binding-site-containing growth factor which contains a growth factor receptor agonist peptide and a collagen-binding peptide, and is also superior in osteogenic ability.Type: GrantFiled: March 26, 2012Date of Patent: February 2, 2016Assignees: SCHOOL JURIDICAL PERSON KITASATO INSTITUTE, NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERSITYInventors: Kentaro Uchida, Koji Naruse, Masashi Takaso, Takehiko Mima, Osamu Matsushita, Takashi Haraguchi, Nozomu Nishi
-
Publication number: 20150335610Abstract: The purpose of the present invention is to provide a therapeutic agent or preventive agent for exacerbation of influenza, specifically to provide a novel pyruvate dehydrogenase kinase 4 (PDK4) inhibitor. The present invention relates to a PDK4 inhibitor, medical composition or cosmetic composition containing as the active ingredient a compound represented by any one of the following general formulas (I) through (III) and a pharmaceutically acceptable ester derivative thereof, or a pharmaceutically acceptable salt of the same.Type: ApplicationFiled: October 17, 2013Publication date: November 26, 2015Applicants: THE UNIVERSITY OF TOKUSHIMA, THE KITASATO INSTITUTEInventors: Satoshi OMURA, Hirofumi NAKANO, Kenzaburo YAMAJI, Tsuyoshi YAMAMOTO, Hiroshi KIDO, Junji CHIDA, Kazuhiko YAMANE
-
Patent number: 9187492Abstract: A compound effective in prevention and treatment of arteriosclerosis with a mechanism different from that of statin drugs has the following formula or a pharmaceutically acceptable salt, solvate, or hydrate thereof: wherein R1 is an aliphatic, alicyclic, or aromatic acyloxy group, or a group of the formula —O—CH(R7)—R8 where R7 is a lower alkoxy group and R8 is an aryl group, and R2 is carboxyl, a lower alkoxycarbonyl group, or an arylmethylcarbamoyl group, or a —CH2-acyloxy group and R3 is an aliphatic, alicyclic or aromatic acyloxy group, provided that at least one of R4 and R3 is a group other than acetoxy, or R2 and R3 taken together form a group of the formula —O—CH(R5)—O— where R5 is an aryl group.Type: GrantFiled: March 25, 2011Date of Patent: November 17, 2015Assignee: School Juridical Person Kitasato InstituteInventors: Hiroshi Tomoda, Tohru Nagamitsu, Daisuke Matsuda, Taichi Ohshiro, Masaki Ohtawa, Satoshi Omura